Acute Lymphoblastic Leukemia Therapeutics Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
Acute Lymphoblastic Leukemia Therapeutics Market |
The global increase in the incidence rate of the disease
presents growth opportunity for the acute lymphocytic leukaemia (ALL)
treatments market. Acute lymphoblastic leukaemia is more common in children
aged 0 to 14 than in those aged 15 and older. However, adults can also develop
acute lymphoblastic leukaemia. Acute lymphocytic/lymphoblastic leukaemia in
children and adults are the two categories into which the acute
lymphocytic leukaemia market is divided.
Numerous recommendations have been made since the COVID-19
virus first surfaced. Even though there are still few data for this population,
the Leukemia Committee of the French Society for the fight against cancers and
leukemias in children and adolescents (SFCE) has proposed more specific
recommendations due to the nature of acute lymphoblastic leukemias and their
treatment in children and adolescents. Even in the absence of symptoms, screen
all patients for COVID-19 before any hospital admission and/or surgery.
Consider testing for COVID-19 twice, at least 12 hours apart, in cases of
neutropenic fever with no other cause or with abnormal chest radiography
findings to rule out genuine infection. Patients who test positive for COVID-19
should, if at all possible, postpone therapy.
Despite being a significant global supplier of medicines,
China's production interruptions caused by the COVID-19 outbreak in some areas
did not affect global supplies, and normal production has since resumed.
However, as the number of cases rises, these factors will impede the market's
expansion during the forecast period.
Comments
Post a Comment